Etoposide Articles
Seattle Genetics slumps on stopping dacetuzumab Phase IIb diffuse large B-cell lymphoma trial
6 October 2009
Samaritan licenses US PBR patent
3 September 2007
Lilly's Almita enters Ph III trial for SCLC
30 October 2006
Additional appros for Nippon Kayaku's anti-tumor agents
28 February 2005
GW gel prevents chemo-related alopecia
6 April 2000
Amdray shows promise in Phase II
4 March 1999
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
Xeloda NDA Backed By FDA Advisory Panel
20 March 1998
AACR Meeting: ImmunoGen's hN901-DM1
21 April 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
B-MS's Etopophos Receives US FDA Approval
9 September 1996
Xenova Starts Trials Of Second Cancer Drug
17 June 1996
New Etoposide Formulation
3 June 1996
FDA Approval For Immunex' Etoposide
25 March 1996
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
Topo I Inhibitors Show Potential In SCLC
6 November 1995
Upjohn And Gensia Revamp Oncolytics Deal
23 October 1995
ImmunoGen's Cancer Antibody
25 September 1995
New MDR And Toxicity Modulating Agents
12 December 1994
MDR: Misunderstood Drug Resistance?
5 December 1994
IND For CTI's Novel Cancer Drug In 1995?
26 September 1994
BTG Cancer Drug Deal With Chinese Firm
1 August 1994
B-MS INTRODUCES NEW ETOPOSIDE FORMULATION
1 August 1994
MATRIX REVEALS ADV DATA AT AACR
18 April 1994
NIPPON KAYAKU LAUNCH IN JAPAN
28 March 1994
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
TAXOL REVEALS FURTHER POTENTIAL
25 October 1993
EC'S CPMP BACKS TAXOL APPROVAL
27 September 1993
TAIWAN SUBSIDIARY PLANNED BY NIPPON KAYAKU
7 June 1993
BRISTOL MYERS SQUIBB REFORMULATION
31 May 1993
CLINICAL PROGRESS WITH TOPO I INHIBITORS
31 May 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
NEW CANCER DRUGS SHINE AT US MEETING
2 November 1992
TAIHO R&D REVEALS NEW CANCER DRUGS
8 June 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
Showing 1-38 of 38 articles
- 1
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
